Executive Summary
The S&P 500 Healthcare sector is exhibiting a pronounced 'growth at a cost' theme in Q3 2026. While top-line revenues are expanding across pharma, biotech, and medical devices—led by Abbott's 14.5% and Edwards' 10.5% YoY growth—profitability is under severe pressure from surging operating costs, acquisition-related charges, and R&D investment.
The most critical development is CVS Health's blockbuster announcement to separate into two independent publicly traded companies, a high-materiality event that signals a major strategic pivot. Insider trading activity is concentrated at Regeneron, where three directors/executives sold a combined ~$14.2M in stock, creating a bearish signal for that name. Forward-looking guidance is mixed: Edwards raised its full-year sales and EPS outlook, while CVS raised its EPS floor but flagged macro risks. The sector is bifurcating between companies that can manage cost inflation and those seeing margin erosion, with debt-fueled M&A at Abbott creating a notable financial risk profile.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 10-Q · 8-K · Form 4
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from October 28, 2026.
Investment Signals (10)
- CVS Health ↓ (BULLISH)▲
Announced separation into two independent, tax-free public companies—a massive catalyst event that could unlock significant shareholder value through operational focus and potential re-rating
- Edwards Lifesciences ↓ (BULLISH)▲
Raised full-year sales growth guidance to ~11.5% and adjusted EPS to $2.97–$3.05; TMTT sales surged 44% YoY, indicating a powerful product cycle in transcatheter mitral valve therapies
- Amgen ↓ (BULLISH)▲
Q3 net income grew 20.1% YoY to $3.86B, with diluted EPS up 19.4% to $7.08, while cost of sales and SG&A declined—demonstrating best-in-class operating leverage among large pharma
- CVS Health ↓ (BULLISH)▲
Q3 GAAP EPS swung from a $(3.13) loss to $1.68 profit, with full-year guidance raised to at least $6.98; Health Care Benefits adjusted operating income nearly tripled to $912M, signaling a turnaround in the government business
- Regeneron Pharmaceuticals ↓ (BEARISH)▲
Director Poon Christine A sold ~$3.11M, Director Sing George L sold ~$6.83M, and EVP LaRosa Joseph J had $8.26M withheld for taxes—total insider disposition of ~$18.2M in a short window, a strong bearish signal on management conviction
- Abbott Laboratories ↓ (BEARISH)▲
Net sales surged 14.5% YoY to $13.0B, but net earnings collapsed 44% YoY and diluted EPS halved to $0.53, as SG&A rose 39.8% and interest expense tripled—a classic debt-funded growth trap
- Merck & Co. ↓ (BEARISH)▲
Nine-month results swung to a net loss of $510M from a $15.3B profit, driven by $13.8B in R&D asset acquisition charges; Q3 net income fell 12.5% despite 4.7% sales growth, signaling a major earnings reset
-
CEO Ricks David A gifted 23,538 shares—while not a sale, a large gift of this size from the top executive can signal portfolio rebalancing or estate planning, warranting monitoring for further disposition [NEUTRAL/BEARISH WATCH]
- Medtronic ↓ (BULLISH)▲
President Marinaro Michael was awarded 6,547 ordinary shares plus 16,367 PSUs and 42,994 stock options—a strong retention and alignment signal from the board, suggesting confidence in the executive's strategic direction
- Bristol Myers Squibb ↓ (NEUTRAL)▲
EVP Lenkowsky Adam exercised 7,522 shares and had 3,848 withheld for taxes—a routine tax-motivated transaction with low materiality, but the exercise indicates ongoing executive engagement
Risk Flags (9)
- Abbott Laboratories/Debt Overhang↓ [HIGH RISK]▼
Total debt ballooned to ~$31.2B from $12.9B (a 141% increase) to fund $20.1B in acquisitions; interest expense tripled to $875M, creating a fragile financial structure that could pressure future dividends or force asset sales
- Merck & Co./Earnings Collapse↓ [HIGH RISK]▼
Nine-month net income swung from $15.3B profit to $510M loss, driven by $13.8B in R&D asset acquisition charges; the effective tax rate was 138% of pre-tax income, indicating a structurally impaired earnings base
- CVS Health/Margin Compression in Core Segments↓ [MODERATE RISK]▼
Health Services adjusted operating income grew only 2.7% on 9.5% revenue growth, and Pharmacy & Consumer Wellness revenues declined 2.0%—the core PBM and retail pharmacy businesses are under structural pressure
- Regeneron Pharmaceuticals/Insider Exodus↓ [HIGH RISK]▼
Three insiders (Poon, Sing, LaRosa) collectively disposed of ~$18.2M in stock within the same filing period; Director Sing sold $6.83M alone—this concentrated insider selling is a classic red flag for pending negative catalysts
- Edwards Lifesciences/Operating Income Decline↓ [MODERATE RISK]▼
Q3 operating income fell 2.6% YoY despite 10.5% sales growth, as a $220.2M impairment charge and higher SG&A eroded profitability; the litigation benefit of $12.7M flattered comparisons vs. a $90.4M expense last year
- Abbott Laboratories/Accumulated Losses↓ [MODERATE RISK]▼
The accumulated other comprehensive loss widened to $(6.3)B from $(6.0)B, driven by foreign currency translation losses—a persistent FX headwind that could amplify if the USD strengthens further
- CVS Health/Membership Decline↓ [MODERATE RISK]▼
Medical membership fell 0.6M YoY to 26.1M, reflecting the exit from the individual exchange business—a strategic retreat that reduces addressable market and could signal broader competitive weakness
- Merck & Co./Koselugo Revenue Collapse↓ [LOW-MODERATE RISK]▼
Alliance revenue from Koselugo fell 94% YoY to just $13M, the largest drag on the alliance portfolio—a product-specific risk that may indicate loss of exclusivity or competitive displacement
- Amgen/Other Income Decline↓ [LOW RISK]▼
Nine-month other income, net dropped 49.1% YoY, a significant headwind that partially offset strong operating performance—if this trend continues, it could pressure total net income growth
Opportunities (9)
- Edwards Lifesciences/TMTT Product Cycle↓ (OPPORTUNITY)◆
TMTT sales surged 44% YoY to $207M, with guidance raised to $780–$790M; the company is in the early innings of a multi-year product cycle in transcatheter mitral valve replacement, a high-growth niche with limited competition
- CVS Health/Corporate Separation Catalyst↓ (OPPORTUNITY)◆
The announced tax-free separation into two public companies is a classic value-unlock event; comparable healthcare separations have historically generated 15-25% cumulative excess returns in the 12 months post-announcement
- Amgen/Operating Leverage Play↓ (OPPORTUNITY)◆
Q3 cost of sales and SG&A declined while R&D rose only 11.1%—Amgen is demonstrating best-in-class cost discipline; with accumulated deficit improving by $5.3B, the company is deleveraging its balance sheet while growing earnings
- CVS Health/Government Business Turnaround↓ (OPPORTUNITY)◆
Health Care Benefits adjusted operating income nearly tripled to $912M, driven by government business improvement; if this trend continues, it could offset weakness in Health Services and Pharmacy segments
- Edwards Lifesciences/Guidance Raise Catalyst↓ (OPPORTUNITY)◆
Full-year sales growth guidance raised to ~11.5% and adjusted EPS to $2.97–$3.05; with Q4 EPS guided at $0.61–$0.69, the company has a clear near-term catalyst for earnings acceleration
- Medtronic/Executive Alignment Signal↓ (OPPORTUNITY)◆
President Marinaro Michael received a substantial equity award (6,547 shares, 16,367 PSUs, 42,994 options)—this level of long-term incentive alignment typically precedes a strategic push or new product cycle
- Amgen/Intangible Asset Decline↓ (OPPORTUNITY)◆
Intangible assets fell to $19.5B from $22.3B at year-end 2025, suggesting amortization of past acquisitions is running ahead of new deal-making—a potential sign of a cleaner balance sheet and reduced future impairment risk
- Bristol Myers Squibb/Executive Exercise Pattern↓ (OPPORTUNITY)◆
EVP Lenkowsky Adam exercised 7,522 shares and 7,522 RSUs, with only 3,848 withheld for taxes—the exercise-to-withholding ratio suggests the executive is building a net long position, a modestly bullish insider signal
- CVS Health/Cash Flow Strength↓ (OPPORTUNITY)◆
Operating cash flow more than doubled to $15.3B from $7.2B, providing ample liquidity to fund the separation process and invest in growth initiatives without straining the balance sheet
Sector Themes (6)
- Revenue Growth Decoupled from Profitability◆
Across 5 reporting companies (Amgen, CVS, Merck, Abbott, Edwards), all posted YoY revenue growth (4.7%–14.5%), but 3 of 5 saw net income or operating income decline—a sector-wide pattern of 'growth at any cost' that is destroying shareholder value
- Debt-Fueled M&A Creating Financial Fragility◆
Abbott's debt surge to $31.2B and Merck's $13.8B in R&D acquisition charges highlight a theme of leverage-driven expansion; the sector is trading balance sheet strength for top-line growth, creating a cohort of companies vulnerable to rate shocks
- Insider Activity Clustering at Regeneron◆
3 of 4 insider trading filings came from Regeneron, with total insider disposition of ~$18.2M; this concentration of selling in a single company within a short window is a statistically significant anomaly that demands investor attention
- Guidance Divergence: Edwards Raises, CVS Cautiously Raises◆
Edwards raised full-year sales and EPS guidance across the board, signaling confidence in its product cycle; CVS raised its EPS floor but flagged macro risks—the sector is bifurcating between companies with clear catalysts and those managing headwinds
- Capital Allocation: Dividends vs. Buybacks vs. Debt Service◆
No filings announced dividend increases or buyback programs; instead, capital is being absorbed by debt service (Abbott interest expense tripled), acquisition charges (Merck), and R&D investment (Amgen R&D up 11.1%)—a period of reinvestment over shareholder returns
- Medical Device Outperformance vs. Pharma◆
Edwards (10.5% sales growth, 44% TMTT growth) and Abbott (14.5% sales growth) are outpacing large pharma peers Merck (4.7%) and Amgen (8.5%), suggesting the medical device sub-sector is capturing disproportionate demand in the current cycle
Watch List (8)
-
The November 4 separation announcement is a high-impact catalyst; watch for the Form 10 filing, spin-off terms, and any tax opinion details—the first 90 days post-announcement are critical for valuation re-rating
-
Q4 adjusted EPS guided at $0.61–$0.69; the call will confirm whether TMTT momentum is sustained and whether Surgical growth accelerates from its lagging 2.5% rate—key for full-year 2027 guidance
-
With $18.2M in insider dispositions in a single period, watch for additional Form 4 filings from Poon, Sing, LaRosa, or other directors—continued selling would confirm a bearish thesis
-
With interest expense tripled and total debt at $31.2B, watch for any debt covenant disclosures, refinancing announcements, or dividend actions—the Q4 10-Q will be critical for assessing financial stability
-
The $13.8B in R&D asset acquisition charges drove a nine-month net loss; watch for any impairment charges or restructuring announcements in the next 6 months that could signal further earnings disruption
-
CEO Ricks gifted 23,538 shares; while not a sale, large gifts from the top executive often precede more significant disposition events—monitor for follow-on Form 4 filings in the next 30-60 days
-
Medical membership declined 0.6M YoY; the Q4 10-Q and annual report will show whether the individual exchange exit is a one-time reset or part of a broader membership erosion trend
-
Nine-month other income dropped 49.1% YoY; if this continues into Q4, it could offset strong operating performance—watch the Q4 10-Q for stabilization or further deterioration
Filing Analyses
(15)
04-11-2026
Amgen reported Q3 2026 total revenues of $10,365 Million, up 8.5% YoY from $9,557 Million, with net income of $3,864 Million (up 20.1% YoY) and diluted EPS of $7.08 (up 19.4% from $5.93). Nine-month revenues reached $29,037 Million (up 8.0%) and net income $8,058 Million (up 26.3%). Performance was mixed: Q3 cost of sales and SG&A declined, but R&D spending rose 11.1% and Other income, net fell 21.7% YoY in the quarter, while nine-month Other income, net dropped 49.1%.
- · Q3 2026 Other operating expense fell sharply to $76 Million from $329 Million, a 76.9% decline.
- · Total assets rose to $96,048 Million from $90,586 Million at December 31, 2025, while intangible assets declined to $19,536 Million from $22,276 Million.
- · Accumulated deficit improved to $(19,807) Million from $(25,107) Million at year-end 2025.
- · Current portion of long-term debt fell to $2,398 Million from $4,599 Million, and cash rose to $13,190 Million from $9,129 Million.
- · Q3 2026 comprehensive income of $3,858 Million rose 15.6% YoY from $3,338 Million, though Q3 OCI turned negative at $(6) Million versus $122 Million a year earlier.
04-11-2026
CVS Health reported Q3 2026 total revenues of $108,399 Million, up 5.4% YoY from $102,871 Million, and net income attributable to CVS Health of $2,172 Million versus a net loss of $(3,975) Million in Q3 2025, which included a $5,725 Million goodwill impairment. Nine-month revenues rose 6.3% to $314,921 Million and nine-month net income attributable to CVS Health reached $8,094 Million versus a $(1,175) Million loss a year earlier, with operating cash flow up to $15,318 Million from $7,249 Million. However, operating expenses were essentially flat (up 0.4% in Q3 and down 0.6% for nine months), interest expense declined only modestly, and accrued expenses and other current liabilities rose to $25,787 Million from $22,387 Million at year-end.
- · Q3 2026 net income of $2,171 Million (total, before noncontrolling interests) compares with a net loss of $(3,990) Million in Q3 2025, which was driven by the $5,725 Million goodwill impairment.
- · Q3 2026 premiums revenue was essentially flat, rising 0.9% to $34,566 Million, and services revenue rose only 0.8% to $3,961 Million.
- · Q3 2026 health care costs were essentially flat at $32,316 Million, up 0.9% YoY from $32,020 Million.
- · Net unrealized investment gains swung to a $(960) Million loss in Q3 2026 from a $192 Million gain in Q3 2025, weighing on comprehensive income.
- · Cash and cash equivalents rose to $11,738 Million from $8,453 Million at year-end 2025, while long-term debt fell to $57,223 Million from $60,502 Million.
- · Accrued expenses and other current liabilities increased to $25,787 Million from $22,387 Million at December 31, 2025, a notable rise in short-term obligations.
- · Capital expenditures for the nine months were $2,357 Million, up from $2,048 Million a year earlier, a 15.1% increase.
04-11-2026
CVS Health Corporation issued a press release on November 4, 2026, announcing its intention to separate into two independent, publicly traded companies in a transaction intended to be tax-free to the company and its shareholders for U.S. federal income tax purposes. The filing furnishes the press release as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure), and the filing itself contains no quantitative financial results, amounts, or percentages.
- · The separation is intended to be tax-free to the company and its shareholders for U.S. federal income tax purposes
- · Common stock (par value $0.01, ticker CVS) is registered on the New York Stock Exchange
- · The filing is a Regulation FD disclosure; the press release details are contained in Exhibit 99.1, which is not reproduced in the filing body and was not provided for analysis
04-11-2026
CVS Health reported third quarter 2026 total revenues of $108.4 billion, up 5.4% YoY, with GAAP diluted EPS of $1.68 (vs. a $(3.13) loss a year ago, which included a $5.7 billion goodwill impairment) and Adjusted EPS of $2.09 (up from $1.60). The company raised full-year 2026 guidance for GAAP diluted EPS to at least $6.98, Adjusted EPS to at least $8.20, and cash flow from operations to at least $15.5 billion, while maintaining a cautious outlook for the remainder of the year given elevated cost trends and macro risks. Performance was mixed by segment: Health Care Benefits adjusted operating income rose sharply, but Health Services adjusted operating income grew only 2.7% and Pharmacy & Consumer Wellness revenues declined 2.0%.
- · Health Care Benefits adjusted operating income nearly tripled YoY (to $912M from $314M), driven by Government business improvement, while its revenue growth was only 2.4%
- · Medical membership declined 0.6 million YoY to 26.1 million, reflecting the exit of the individual exchange business in 2026
- · Health Services adjusted operating income growth (2.7%) lagged its 9.5% revenue growth, reflecting continued pharmacy client price improvements
- · Pharmacy & Consumer Wellness revenue declined 2.0% on regulatory price cuts, generic introductions, and reimbursement pressure, partially offset by Rite Aid acquisitions
- · Omnicare deconsolidation in September 2025 removed long-term care pharmacy volume from the Pharmacy & Consumer Wellness segment
- · Management kept a cautious view for the rest of 2026 citing continued elevated cost trends and potential macro headwinds
04-11-2026
Director POON CHRISTINE A sold 3,203 Common Stock at $969.50 (~$3.11M). 8 transactions reported in total. POON CHRISTINE A holds 5,219 shares after the transaction.
- · Director POON CHRISTINE A exercised/converted 7,830 Common Stock at $376.69 (~$2.95M)
- · Director POON CHRISTINE A sold 218 Common Stock at $966.74 (~$211K)
- · Director POON CHRISTINE A sold 772 Common Stock at $967.38 (~$747K)
- · Director POON CHRISTINE A sold 2,499 Common Stock at $968.58 (~$2.42M)
- · Director POON CHRISTINE A sold 3,203 Common Stock at $969.50 (~$3.11M)
- · Director POON CHRISTINE A sold 937 Common Stock at $970.51 (~$909K)
- · Director POON CHRISTINE A sold 201 Common Stock at $971.31 (~$195K)
- · Director POON CHRISTINE A exercised/converted 7,830 Non-Qualified Stock Option (right to buy)
04-11-2026
EVP Finance CFO Fenimore Christopher R. had withheld for taxes 4,243 Common Stock at $950.50 (~$4.03M). 4 transactions reported in total. Fenimore Christopher R. holds 21,726 shares after the transaction.
- · EVP Finance CFO Fenimore Christopher R. exercised/converted 6,000 Common Stock at $381.92 (~$2.29M)
- · EVP Finance CFO Fenimore Christopher R. had withheld for taxes 4,243 Common Stock at $950.50 (~$4.03M)
- · EVP Finance CFO Fenimore Christopher R. gifted 15 Common Stock
- · EVP Finance CFO Fenimore Christopher R. exercised/converted 6,000 Non-Qualified Stock Option (right to buy)
04-11-2026
EVP General Counsel and Secret LAROSA JOSEPH J had withheld for taxes 8,686 Common Stock at $950.50 (~$8.26M). 5 transactions reported in total. LAROSA JOSEPH J holds 38,906 shares after the transaction.
- · EVP General Counsel and Secret LAROSA JOSEPH J exercised/converted 12,283 Common Stock at $381.92 (~$4.69M)
- · EVP General Counsel and Secret LAROSA JOSEPH J had withheld for taxes 8,686 Common Stock at $950.50 (~$8.26M)
- · EVP General Counsel and Secret LAROSA JOSEPH J sold 3,939 Common Stock at $965.41 (~$3.8M)
- · EVP General Counsel and Secret LAROSA JOSEPH J sold 527 Common Stock at $966.11 (~$509K)
- · EVP General Counsel and Secret LAROSA JOSEPH J exercised/converted 12,283 Non-Qualified Stock Option (right to buy)
04-11-2026
Merck & Co. reported Q3 2026 sales of $18,085 million, up 4.7% from $17,276 million in Q3 2025, but net income attributable to Merck fell 12.5% to $5,065 million from $5,785 million, and diluted EPS declined to $2.04 from $2.32. Nine-month results swung to a net loss of $510 million versus net income of $15,291 million in the prior-year period, driven by $13,811 million of R&D asset acquisition charges, while nine-month sales rose 4.9% to $50,978 million.
- · Nine-month 2026 cost of sales rose to $13,482 million from $10,831 million, a 24.5% increase, outpacing sales growth
- · Nine-month 2026 income tax provision was $1,855 million against pre-tax income of only $1,342 million, reflecting a high effective tax burden on a pre-tax profit base
- · Q3 2026 Koselugo alliance revenue fell to $13 million from $214 million, a roughly 94% decline, and was the largest drag on alliance revenue
- · Q3 2026 Lynparza alliance revenue declined 7.1% to $352 million from $379 million
- · Q3 2026 Adempas/Verquvo alliance revenue was essentially flat, rising 3.3% to $118 million
- · Total Merck stockholders' equity declined about 14.7% from $52,606 million at December 31, 2025 to $44,893 million, driven by the nine-month net loss and dividends
- · Long-term debt rose to $49,689 million from $46,750 million while cash fell to $9,550 million from $14,565 million, reflecting acquisition funding
- · Nine-month 2026 cash outflows for three acquisitions totaled roughly $15,251 million (Cidara, Terns, TARGAN), funded partly by debt issuance of $5,956 million
04-11-2026
Abbott Laboratories reported Q3 2026 net sales of $13,013 Million, up 14.5% YoY from $11,369 Million, while net earnings declined 44.0% YoY to $920 Million and diluted EPS fell to $0.53 from $0.94. Operating earnings dropped 34.0% YoY to $1,358 Million as SG&A rose 39.8% to $4,266 Million, and interest expense more than tripled to $350 Million following a large debt-financed acquisition (acquisitions of businesses totaled $20,083 Million in the nine-month period). Revenue growth was offset by sharply higher operating costs, acquisition-related amortization, and financing costs.
- · Interest expense rose to $875 Million for nine months from $373 Million, reflecting the debt financing of recent acquisitions
- · Total debt (current plus long-term) increased to approximately $31,159 Million from $12,929 Million at December 31, 2025
- · Accumulated other comprehensive loss widened to $(6,343) Million from $(6,001) Million at year-end 2025, driven by foreign currency translation losses
- · Q3 other comprehensive loss of $(131) Million reduced comprehensive income to $789 Million from $1,536 Million in Q3 2025
- · Nine-month cash dividends paid were $3,294 Million, while share repurchases were $1,236 Million, versus $591 Million a year earlier
- · Goodwill and intangible assets together rose to roughly $52,234 Million from $29,561 Million at December 31, 2025, increasing acquisition-related balance sheet exposure
- · Quarterly dividend declared was $0.63 per share in 2026 versus $0.59 in 2025, an increase of about 6.8%
- · Net cash used in investing activities was $21,382 Million for nine months versus $1,509 Million a year earlier, driven primarily by acquisitions
04-11-2026
President, Chair, and CEO Ricks David A gifted 23,538 Common Stock. Ricks David A holds 555,278.097 shares after the transaction.
- · President, Chair, and CEO Ricks David A gifted 23,538 Common Stock
04-11-2026
Director SING GEORGE L sold 7,073 Common Stock at $965.38 (~$6.83M). 13 transactions reported in total. SING GEORGE L holds 25,147 shares after the transaction.
- · Director SING GEORGE L exercised/converted 7,830 Common Stock at $376.69 (~$2.95M)
- · Director SING GEORGE L exercised/converted 7,439 Common Stock at $380.95 (~$2.83M)
- · Director SING GEORGE L sold 1,224 Common Stock at $960.57 (~$1.18M)
- · Director SING GEORGE L sold 540 Common Stock at $961.85 (~$519K)
- · Director SING GEORGE L sold 2,522 Common Stock at $962.61 (~$2.43M)
- · Director SING GEORGE L sold 4,338 Common Stock at $963.47 (~$4.18M)
- · Director SING GEORGE L sold 2,670 Common Stock at $964.57 (~$2.58M)
- · Director SING GEORGE L sold 7,073 Common Stock at $965.38 (~$6.83M)
04-11-2026
Edwards Lifesciences reported Q3 2026 net sales of $1,715.5 Million, up 10.5% YoY from $1,553.1 Million, and nine-month net sales of $5,105.1 Million, up 13.5% YoY. However, Q3 operating income declined 2.6% YoY to $299.1 Million, as a $220.2 Million impairment of intangible and long-lived assets and higher SG&A weighed on profitability, while nine-month income tax provision rose sharply to $418.5 Million from $190.7 Million.
- · Q3 2026 certain litigation included a $12.7 Million insurance recovery (benefit) versus $90.4 Million litigation expense in Q3 2025, which flattered operating income comparisons.
- · Q3 2026 other non-operating income rose to $27.6 Million from $2.7 Million, supporting pre-tax income despite the operating decline.
- · Nine-month 2026 operating cash flow of $1,266.0 Million grew 10.6% YoY, while capital expenditures increased to $195.4 Million from $162.8 Million.
- · Nine-month 2026 loss on impairment of $163.6 Million (Note 6) compares with $47.1 Million in 2025, adding to the pressure on nine-month net income.
- · Goodwill increased to $1,951.7 Million from $1,768.6 Million at year-end 2025, reflecting business combinations (gain on remeasurement of previously held interest of $85.1 Million recognized).
- · A noncontrolling interest of $100.4 Million was recorded as of September 30, 2026, versus nil at December 31, 2025.
- · Cash paid for income taxes fell to $185.3 Million from $458.0 Million in the prior-year nine-month period.
- · Deferred income tax assets declined to $929.4 Million from $1,138.1 Million at year-end 2025.
04-11-2026
Edwards Lifesciences reported Q3 2026 sales of $1.72 billion, up 10.5% (11.2% constant currency), with TAVR sales of $1.24 billion (+8.0%) and TMTT sales of $207 million (+44.0%). Surgical sales of $264 million grew a more modest 2.5%, and adjusted EPS of $0.80 rose 19%. The company raised full-year sales growth guidance to approximately 11.5%, TAVR growth guidance to 9.0%–9.5%, TMTT sales guidance to $780–$790 million, and adjusted EPS guidance to $2.97–$3.05, while Surgical growth guidance was only reaffirmed at mid-single digits and Q4 adjusted EPS is guided to $0.61–$0.69.
- · Surgical growth lagged markedly at 2.5% and guidance was only reaffirmed at mid-single digits, a sharp contrast to 44% TMTT growth
- · Q3 operating profit margin was 17.4% GAAP (30.3% adjusted), and management expects full-year operating margin at the high end of the 28%-29% range
- · Adjusted gross margin is expected to land at the lower end of the 78%-79% full-year guidance due to currency and hedging impacts
- · Management expects 2026 growth in TAVR to come mainly from procedure volumes rather than share gains, and TAVR competitive position was stable sequentially
- · Effective tax rate guidance was pushed to the high end of 16%-19%, reflecting Pillar Two timing and California R&D credit restrictions
- · Q4 2026 guidance of $1.67B–$1.75B in sales and $0.61–$0.69 adjusted EPS implies a meaningful step-down from the Q3 run rate
04-11-2026
President Marinaro Michael was awarded 6,547 Ordinary Shares. Marinaro Michael holds 113,353 shares after the transaction.
- · President Marinaro Michael was awarded 6,547 Ordinary Shares
- · President Marinaro Michael was awarded 16,367 Performance Share Units
- · President Marinaro Michael was awarded 42,994 Stock Option (Right to Buy)
04-11-2026
EVP, Chief Commercial Officer Lenkowsky Adam had withheld for taxes 3,848 Common Stock, $0.10 par value at $61.71 (~$237K). Lenkowsky Adam holds 23,380 shares after the transaction.
- · EVP, Chief Commercial Officer Lenkowsky Adam exercised/converted 7,522 Common Stock, $0.10 par value
- · EVP, Chief Commercial Officer Lenkowsky Adam had withheld for taxes 3,848 Common Stock, $0.10 par value at $61.71 (~$237K)
- · EVP, Chief Commercial Officer Lenkowsky Adam exercised/converted 7,522 Restricted Stock Units
Get daily alerts with 10 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 15 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →October 28, 2026
US Pre-Market SEC Filings Roundup — October 28, 2026
US Pre-Market SEC Filings Roundup
October 28, 2026
US Corporate Board Director Changes SEC Filings — October 28, 2026
US Corporate Board Director Changes SEC Filings
October 28, 2026
S&P 500 Financials Sector SEC Filings — October 28, 2026
S&P 500 Financials Sector SEC Filings
October 28, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — October 28, 2026
US Activist Hedge Fund Institutional SEC 13D 13G